Activity Date: 04/18/2023
Prior to the presentation, breakfast will be served from 7:00-7:15 AM Eastern. The program should begin right at 7:15 AM Eastern; however, small delays are possible due to the meal. We thank you in advance for your patience.
Bipolar disorder (BD) is a lifelong mental health condition that is characterized by recurrent episodes of emotional manic or depressive symptoms. There are numerous traditional therapies used to treat acute mania and depressive episodes. Because of the complexities surrounding these treatment regimens, low treatment response, and adverse effects experienced with the medications, nonadherence is common amongst patients with BD. With nonadherence being such a substantial concern, pharmacists can play an integral role in ensuring that hesitations and expectations are addressed at the initiation of therapy to improve the patient’s understanding and attitude toward necessary medications. This activity will cover the challenges associated with BD, treatment strategies, recent treatment advancements, investigational therapies, and the impact pharmaceutical interventions can have on disease outcomes. With greater understanding of the clinical burden, stigma, and adherence barriers associated with BD, pharmacists will be equipped to help better serve and manage patients.
PARTICIPATE IN POLLS
HOW TO RECEIVE CREDIT
Please follow the instructions below to claim your credit:
NOTE: Participation data will not be uploaded into CPE monitor if you do not have your NABP (e-profile ID) number and date of birth entered in your profile.
All participants must request credit by June 18, 2023
Stephen R. Saklad, PharmD, BCPP
View biographical informationAAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.